Type 2 diabetes mellitus is a risk factor for pancreatic cancer which is increasing worldwide. A research group from Turkey has found that the use of a tumor marker, Ca 19-9, in diabetics with a ...

Tumor markers for pancreatic cancer often include CA 19-9 or CEA. However, neither is accurate enough to allow healthcare professionals to diagnose pancreatic cancer without other tests.

CA19-9 is the most widely used pancreatic cancer serum markers. Its level has been shown to correlate with the TNM staging and the tumor sizes in patients with pancreatic cancer.

Compared with the standard tumor marker CA 19-9, Tumor M2-PK showed a similar diagnostic sensitivity and specificity (71 vs 68%) for pancreatic carcinoma. [16] ...

Tumor markers are biomarkers made by cancer cells or produced by the body in response to cancer. The tumor markers commonly used for pancreatic cancer are CA19-9 and CEA.

Patients were evaluated for objective tumor response, changes in the serum tumor marker CA 19-9, time to tumor progression (TTP), survival, and safety. RESULTS: Forty-five patients were treated.

To investigate the prognostic value of quality of life (QOL) relative to tumour marker carbohydrate antigen (CA) 19-9, and the role of CA 19-9 in estimating palliation in patients with advanced ...

A new study suggests that rather than screening for disease, blood tumor markers could be useful in monitoring therapeutic outcomes in those with already established disease.

Type 2 diabetes mellitus is a risk factor for pancreatic cancer which is increasing worldwide. A research group from Turkey has found that the use of a tumor marker, Ca 19-9, in diabetics with a ...